Wednesday, June 10, 2026

Patent intelligence · WO

WO 2025262150

MOLÉCULES DE RECRUTEMENT D'ANTICORPS

granted A61K 39/ 00 A IA61K 47/ 54 A IA61K 47/ 62 A IA61K/4764
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 20
Applicant portfolio 25
Patent details — WO 2025262150
Jurisdiction
WO
Status
granted
Grant date
Dec 26, 2025
Expiration
Dec 21, 2045
Applicant
ABLYNX NV [BE]
CPC classes
A61K 39/ 00 A I, A61K 47/ 54 A I, A61K 47/ 62 A I, A61K/4764
View on Google Patents ↗

Quick answer

WO 2025262150 (MOLÉCULES DE RECRUTEMENT D'ANTICORPS) is held by ABLYNX NV [BE]. Status: granted. Granted Dec 26, 2025. Expires Dec 21, 2045 (20 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Applicant
ABLYNX NV [BE]
Grant date
Expiration
Claims
CPC classes
A61K 39/ 00 A I, A61K 47/ 54 A I, A61K 47/ 62 A I, A61K/4764, A61K/47641, A61K/4765

More from ABLYNX NV [BE]

Related pharmaceutical patents in our USPTO index.

  1. WO 2026078159

    AGENTS D'ACTIVATION DE CELLULES IMMUNITAIRES ET PROCÉDÉS LES COMPRENANT

    ABLYNX NV [BE] · Expires Apr 11, 2046

    granted
  2. WO 2026030375

    NANOPARTICULES LIPIDIQUES ET LEURS PROCÉDÉS DE FABRICATION ET D'UTILISATION

    GENZYME CORP [US] · Expires Jan 31, 2046

    granted
  3. AR 133055

    DOMINIOS VARIABLES ÚNICOS DE INMUNOGLOBULINA DIRIGIDOS A PD-L1

    ABLYNX NV [BE] · Expires Aug 15, 2045

    granted
  4. MX 2025007399

    PROTEIN-BASED CONJUGATION CARRIERS

    ABLYNX NV [BE] · Expires Jul 27, 2045

    granted
  5. WO 2025133166

    VÉHICULES À BASE DE PROTÉINES POUR CONJUGAISON D'AMINE SPÉCIFIQUE À UN SITE

    ABLYNX NV [BE] · Expires Jun 21, 2045

    granted
  6. WO 2025133252

    DOMAINES VARIABLES UNIQUES D'IMMUNOGLOBULINE CIBLANT CEACAM5

    ABLYNX NV [BE] · Expires Jun 21, 2045

    granted
  7. WO 2025133253

    EXCIPIENTS DE CONJUGAISON PROTÉINIQUES POUR ADMINISTRATION INTRANUCLÉAIRE

    ABLYNX NV [BE] · Expires Jun 21, 2045

    granted

Frequently asked questions

What is US patent 2025262150?

WO 2025262150 (MOLÉCULES DE RECRUTEMENT D'ANTICORPS) is held by ABLYNX NV [BE]. Status: granted. Granted Dec 26, 2025. Expires Dec 21, 2045 (20 years remaining) — relevant for patent-cliff and LOE planning.

Who owns WO 2025262150?

ABLYNX NV [BE] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.

When does WO 2025262150 expire?

Our index shows an expiration date of Dec 21, 2045 (20 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.